Independent Conference Coverage: Expert Analyses of Atopic Dermatitis Research Results and Their Potential Impact on Patient Care*

Download All
AAAAI February 26 - March 1, 2021, AAD VMX April 23-25, 2021; Virtual
Review the latest AD management data with Capsule Summaries and gain expert insights from a brief commentary covering key studies from the 2021 AAAAI and AAD conferences.

Highlights

Capsule Summary Slidesets

Skin pain is a separate and highly bothersome symptom for children with AD.

Released: June 11, 2021

Study suggests that treatment with abrocitinib 200 mg QD results in a greater and more rapid response vs dupilumab, as assessed using stringent endpoints.

Released: June 15, 2021

Rapid, clinically meaningful, and continual improvement in itch observed with ruxolitinib cream for patients with atopic dermatitis.

Released: June 18, 2021

Case series suggests efficacy of itraconazole for the treatment of dupilumab facial redness.

Released: June 10, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Incyte Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue